Bio-Gene Technology Limited (ASX:BGT)
Australia · Delayed Price · Currency is AUD 0.0180
+0.0010 (5.88%)
Sep 18, 2026, 2:29 PM AEST
Bio-Gene Technology Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
7.45M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | - | - | - |
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | 18.32K | -130.91K | -87.72% |
| Jun 30, 2023 | 149.23K | -296.49K | -66.52% |
| Jun 30, 2022 | 445.73K | 383.12K | 611.91% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 7.71M |
| Acrux | 6.58M |
| Tissue Repair | 2.99M |
| Vectus Biosystems | 2.77M |
| Cambium Bio | 1.23M |
| Biotron | 525.87K |
| ReNerve | 510.36K |
| AdAlta | 404.25K |